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Abstract
This study documents how people who inject drugs (PWID) in rural Puerto Rico perceive 
payments for participating in HIV epidemiological studies. In-depth interviews were conducted 
among a subset (n = 40) of active PWID older than 18 years of age who had been previously 
enrolled in a much larger study (N = 360). Findings suggest that financial compensation was the 
main motivation for initially enrolling in the parent study. Then, as trust in the researchers 
developed, participants came to perceive compensation as part of a reciprocal exchange in which 
they assisted researchers by providing a trustful account of their experiences and researchers 
reciprocated with financial support.
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Although some kind of compensation for participating in scholarly studies is commonly part 
of the research enterprise among this population (Dickert & Grady, 1999; Fisher, 2004) and 
is currently expected, not only by participants but also by researchers who argue that they 
can’t rely on altruistic participation (Abadie, 2010), this practice raises significant ethical 
questions. Some scholars argue that moderate payments do not negatively affect research 
participants (Halpern, Karlawish, Casarett, Berlin, & Asch, 2004), but many others argue 
that financial compensation, particularly in the case of vulnerable research populations, can 
unduly influence them to choose to participate (Gelinas et al., 2018; Largent, Grady, Miller, 
& Wertheimer, 2013; Wong & Bernstein, 2011). Some caution that financial compensation 
effectively restricts research participants’ ability to provide free, uncoerced, and informed 
consent (Grady, 2001) and prompts participants to minimize or neglect risk taking (Bentley 
& Thacker, 2004; Macklin, 1981) or to engage in deception (Devine et al., 2015; Dickert, 
2013) Table 1 provides a summary description of the mainthemes that emerged during the 
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analysis. In the area of substance abuse research, some have suggested that financial 
compensation raises ethical questions because research participants might use financial 
compensation to acquire drugs (Brody & Waldron, 2000; Koocher, 1991). Such concerns 
have led some proponents to advocate the elimination of financial compensation (Largent & 
Fernandez Lynch, 2017; McNeill, 1997; Reiser, 2005).
Despite having the best interests of research participants in mind, such proposals might have 
unintended consequences, making it harder to conduct valuable research that could benefit 
vulnerable research participants and their communities. Recruiting people who inject drugs 
(PWID) into participating in community health research is critical if we are to make a dent 
in the HIV epidemic in the United States and elsewhere. Monetary payments have proven 
effective in increasing HIV testing, antiretroviral therapy adherence, and overall HIV 
treatment outcomes (Bassett, Wilson, Taaffe, & Freedberg, 2015; Czaicki, Mnyippembe, 
Blodgett, Njau, & McCoy, 2017; de Walque et al., 2015). Payments have also proven 
effective in increasing hepatitis B vaccination among PWID (Topp et al., 2013). In addition, 
financial compensation can contribute to the recruitment of marginalized or hard-to-reach 
populations, enhancing thus the validity and social value of research (Abdul-Quader et al., 
2006; Festinger et al., 2005; Fry, Hall, Ritter, & Jenkinson, 2006).
Injection drug use is one of the main causes of HIV transmission on the U.S. mainland and 
in U.S. territories, as contaminated blood is shared through syringes and injection equipment 
(Doerrbecker et al., 2013; Koester, Glanz, & Barón, 2005). A shift from prescription opioid 
use to illicit intravenous drug use has resulted in an increase of HIV and hepatitis C virus 
(HCV) transmission, particularly in rural areas (Van Handel et al., 2016). The most recent 
HIV surveillance data from the U.S. Centers for Disease Control and Prevention (CDC) 
indicate that Puerto Rico hosts one of the highest incidences of HIV infection in the United 
States. In 2010, the island reported 28.2 new HIV infections per 100,000 residents, a rate 
more than 1.5 times higher than that of the U.S. average and the third highest among all 50 
states and six dependent areas in the nation (CDC, 2010). In addition to bearing a 
disproportionate burden of HIV disease in the country, Puerto Rico is the site of a very 
different epidemic from that operating on the continental mainland. Where only 8.3% of new 
HIV infections in the contiguous states were related to injection drug use in 2010, more than 
20% of new diagnoses in Puerto Rico listed intravenous drug use as their cause (CDC, 
2010). A study of PWID in metropolitan San Juan showed a 17% HIV prevalence and a 90% 
HCV prevalence (Reyes et al., 2006). In addition, a more recent study among rural PWID in 
Puerto Rico documented a 6% HIV prevalence and a 78.4% HCV prevalence (Abadie, 
Welch-Lazoritz, Khan, & Dombrowski, 2017).
Ethical debates on the issue of financial compensation among PWID enrolled in community 
health studies have usually relied on a normative ethics approach, without considering how 
participants perceive the role of financial compensation in their decision-making process 
(Ackerman, 1989; Barratt, Norman, & Fry, 2007). By drawing on the experiences of PWID 
who were previously enrolled in the Vida, Accion, Salud community study in rural Puerto 
Rico, the present study contributes to the literature on the ethics of financial compensation in 
research involving human subjects, particularly epidemiological or behavioral studies of 
substance abuse. Using qualitative methods involving 40 semistructured interviews with 
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active PWID, all 18 years old and older, we explored participants’ motivations to enroll, 
including the role of financial compensation, as well as participants’ views on the 
relationship between financial compensation and research trust. The study also asked 
participants about their preferred form of financial compensation.
METHOD
Participants
In-depth interviews (n = 40) were conducted from March to April 2017 among active PWID 
men 18 years of age or older who resided in the localities of Cidra, Cayey, Aguas Buenas, 
and Comerio in rural Puerto Rico. Our decision not to include women reflected the fact that 
women constituted a significant minority—around 10%—of PWID in rural Puerto Rico. 
Participants’ sociodemographic profile seems similar to other groups of PWID living on the 
island. More than three fourths (78.4%) tested positive for hepatitis C during the rapid test, 
whereas 6.0% tested positive for HIV. All 19 HIV positive participants were HCV 
coinfected. Approximately 90.5% (n = 285) were male, and 93.3% were born in Puerto 
Rico. Most PWID who declared to have been born abroad had been born in the continental 
United States. The sample had a mean age of 41.8 years (range = 18–70 years) and an 
average annual per capita income of $4,452. Participants were mostly (85.9%) unemployed, 
21.9% were homeless at the time of their interview, and 52.4% were high school graduates 
(or higher). Only 2.9% of participants were currently married, though an additional 19.4% 
were living together as married, whereas 47% were single and never married (the remaining 
30.8% were separated, divorced, or widowed; Abadie, Welch-Lazoritz, Gelpi-Acosta, Reyes, 
& Dombrowski, 2016)
Participants were selected purposefully from a larger ongoing, multiyear National Institutes 
of Health/ National Institute on Drug Abuse–funded parent project on social networks and 
HIV/ HCV risk in rural Puerto Rico conducted between April 2015 and December 2016. 
The parent study is divided into three phases, with the first phase being an epidemiological 
risk survey, HIV and HCV testing to assess sexual and injection risk behaviors of PWID 
residing in four rural localities (Cidra, Cayey, Aguas Buenas, and Comerio) and an 
evaluation of the degree of access to health-promoting services (see Abadie et al., 2017, for 
further description). Phase 1 included 315 active PWID, all 18 years old or older, who were 
recruited using respondent-driven sampling, a well-established sampling methodology for 
recruiting hidden and hard-to-reach populations (Abdul-Quader et al., 2006; Heckathorn, 
Semaan, Broadhead, & Hughes, 2002; Johnston, Chen, Silva-Santisteban, & Raymond, 
2013).
Procedure
In the parent study, using respondent driven sampling, recruitment was initiated by starting 
with two “seeds,” or key participants, in each of the four municipalities. Participants 
received $25 in compensation and were given the chance to become recruiters. After 
securing consent, they were provided with three referral coupons to recruit other PWID who 
had not previously participated in the study. Every eligible referral earned the recruiter an 
additional $10; in total, this produced 307 referrals. For the second phase, we engaged in 
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ethnographic research with 34 key respondents to learn more about injection risk practices 
and the structure of their social networks; this included visiting their homes, shooting 
galleries, and other locations where they might inject. In this phase we recruited an addition 
45 participants who were part of the key respondents’ ego networks and who had not 
participated in the first phase of the study. Finally, for the third phase, we selected 24 
participants from the previous two phases to participate in a weeklong training in safe 
injection methods.
For the current study on participants’ views of financial compensation, we secured approval 
from the University of Nebraska–Lincoln Institutional Review Board’s (IRB’s) Committee 
on Human Research before we initiated data collection. All participants provided written 
consent at the study’s office, which was located in Cidra, prior to enrollment in the study. 
The informed consent form was modeled by previous research with PWID in this context 
and written in Spanish. A written copy of the consent form included contact numbers for the 
principal investigator (PI) as well as the IRB. To ensure that participants fully grasped the 
main information contained in the consent form, we asked follow-up questions to assess 
their comprehension, such as, “What is the aim of the study?” and “What are we asking you 
to do?” To ensure confidentiality, participants were identified through a unique ID code, 
which also facilitated the linking of participant data with data gathered through the parent 
study (such as demographics, HIV/HCV status, polysubstance and injection drug use, and 
injection risk behaviors). Participants in our study received $30 in cash and were handed 
pamphlets with information about how to prevent HIV/HCV transmission.
A community advisory board (CAB) of eight active PWID who had participated in the 
parent study was established prior to collecting data. Input of the CAB was sought in 
drafting the research design and the recruitment and consent procedures, to ensure their 
cultural appropriateness and sensitivity to our study population. CAB members met twice, 
once at the beginning of the study and once the study was completed to discuss research 
findings. CAB members were not recruited as research subjects, thus preserving their 
advisory role.
Interview format
In-depth interviews were conducted by the PI, who has extensive experience not only in this 
technique but also in working with injection drug users in Puerto Rico. With the permission 
of participants, all interviews were audiotaped at the research office site in Cidra, a place 
already familiar to study participants. We collected demographic data such as age, 
education, income, costs of acquiring drugs, frequency of drug use, and access to health 
care, complementing the broader demographic information, risk profiles, and HIV/HCV 
status data available through the parent study. The main focus of the interviews was to 
document why participants had been motivated to enroll in the parent study as well as their 
views on financial compensation in community-based, epidemiological studies involving 
PWID. A semistructured questionnaire asked participants about the role of financial 
compensation in their decision-making process. A probe introducing a hypothetical scenario
—”Would you enroll in a study where researchers did not respect you but paid you a 
considerable amount?”—was used to elicit views about this topic. We also asked participants 
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about the role financial compensation played in their motivation to enroll, researchers’ 
obligations toward participants, and their own obligations toward research participation. 
Finally, we collected data about the participants’ disposition to participate in a study that 
offered an equivalent amount in the form of a gift card instead of cash.
Data analysis
The audio recordings were transcribed, and all personal identifiers were removed. The 
qualitative analysis software MAXQDA was used to manage coding. Data analysis was 
conducted by the PI. Codes were developed to convey the wide arrange of themes present in 
the narratives of PWID. An audit trail was maintained to keep track of how and why analytic 
decisions were made, and a codebook was developed to describe and define all study codes. 
As it is practiced in qualitative analysis, these codes were iteratively revised and regrouped 
until they eventually represented a set of higher level axial codes comprehensively 
describing participants’ perceptions regarding financial compensation. Following the 
grounded theory approach (Glaser & Strauss, 1967), the interpretation of the data emerged 
inductively from the data, instead of imposing a preexisting theoretical framework to fit the 
data.
RESULTS
Motivations to participate: Money helps
Receiving financial compensation was initially the main motivation and, in some cases, the 
only reason to enroll in the study. Some PWID inject as many as eight to 10 times a day, 
investing a significant amount of financial resources. In addition, frequent heroin users 
struggle to avoid the painful symptoms of heroin withdrawal that they experience if they 
can’t find a dose to relieve the nausea, vomiting, stomach pain, shivering, and general 
discomfort that follow. A participant provides a clue about his decision-making process:
I’ll tell you, the first time I participated [it was] because I was very sick and I 
needed the money. Remember that, when we first came in the morning, you helped 
us—if we were sick you gave us some money first[, saying]: “take this so you can 
take care of things and then come back ready.” Money helped us quite a bit.
(Participant A)
Participant B, a close associate of Participant A, provides a similar rationale: “I was even 
more determined [to participate] because I am using and needed the money.”
Almost nine of 10 participants were unemployed, and finding work in the informal economy 
or “hustles” was one of their main sources of income. For some participants, research studies 
become just another hustle, an opportunity to make money: “I am hustling, always hustling 
and I could really use that money” (Participant C).
Our respondent-driven sampling, which offered additional compensation for participant 
referrals, was also seen as an additional opportunity to increase income:
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Honestly, for the money. [They told me] that they were giving away $35 for 
coming, answering some questions and the HIV tests. And that if you were able to 
bring more people to the study you would receive $10 more.
(Participant D)
One of the few middle-class participants enrolled in our study had no doubts about his 
motivations to participate in the study: “Knowing that I would be paid that was the main 
motivation—not only in my case, but for the overwhelming majority of people. And if 
somebody tells you otherwise, they’re a liar” (Participant E).
Although financial compensation was initially the only motivation for some participants, 
others were also interested in receiving results from HIV/HCV tests, which were conducted 
anonymously and confidentially. Because such testing was done as part of a research study, 
participants were not subjected to the mandatory reporting requirements established by the 
epidemiological surveillance programs conducted by the local Department of Health, 
something they appreciated as well:
Well, it was beneficial economically and besides I got HIV tested. I could know if I 
had the virus, [and] that it was something I was really interested in finding out.
(Participant F)
Somebody told me about the study and that you were paying for it. One afflicted by 
the vice is always in need [of money] so I came in and took advantage of this 
opportunity. I also wanted to know about the [HIV/HCV] test, get the result, and 
since it was for free I took advantage of it too.
(Participant G)
It [the financial compensation] helped because we are users … do you understand? 
But I did it not mainly for the money, I was more interested in the test.
(Participant H)
Is financial compensation coercive?
All participants agreed in their assessment that the need to avoid “dope sickness,” or the 
effects of heroin withdrawal, placed them in a relatively vulnerable position as prospective 
research subjects. If PWID are undergoing the effects of heroin withdrawal when they have 
to make a decision about enrolling in a research study, then issues that are important to them 
like anonymity or confidentiality might be overlooked in their quest to secure the resources 
required to afford their “cure,” as they call the much-needed dose. Some participants seem to 
reassert the validity of the principle of respect, noting that they are entitled to make a 
decision about whether to participate in the study. The following passage between the PI and 
one participant illustrate many participants’ perspective:
Participant: If one is sick [experiencing heroin withdrawal], desperate, it is true that the 
user can’t say “no” You do whatever it is that has to be done. He’s going to do whatever it 
takes to get the money, so if he has to participate in a study he’s gonna do it, out of 
necessity, I know that.
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Investigator: Would you participate even if you have doubts or don’t want to do it?
Participant: Yes, even if you don’t want to do it— if they come and tell you, “I am going to 
give you $30 …”
Investigator: Even without the anonymity and confidentiality that you told me you value as 
a participant?
Participant: Without anything. [They say,] “tell me your name, give me your social security 
number,” and you will provide it because they’ll pay you. Do you understand? You’ll do it 
because you’re sick and you’re going to provide it to them coerced, because they are going 
to pay you. If you are sick—even without confidentiality—you are going to participate 
because you need money to get relief for yourself. (Participant I)
Another participant provides a vivid description of what it feels like to suffer from heroin 
withdrawal and what effects it might have on participants’ disposition to enroll in a 
community health study:
Addiction is very powerful. If I was sick [from heroin withdrawal], I wouldn’t be 
sitting here with you right now. But now I am cured. I have all the time in the world 
to be here with you because now I am feeling the way I should. … It’s not in me, 
this is called ‘addiction,’ I am addict, you know? Even to brush your teeth—I wake 
up in the morning without my cure and I put the toothbrush in the mouth to wash 
my teeth and I vomit. I can’t do it! I can’t function, I can’t! You can’t function until 
you get your cure, you don’t tie your shoelaces until you get your cure, nothing! 
The heroin sickness is strong, you feel it in your body.
(Participant J)
Money does not buy trust
Participants are aware that financial compensation can coerce or unduly influence their 
decision-making process, particularly if they are in a vulnerable situation where they are 
trying to avoid the effects of heroin withdrawal. But at the same time, participants recognize 
that money—while initially ensuring their participation—cannot, in and of itself, buy trust:
Trust has nothing to do with it [payment]. If they give you $30 to cure yourself you 
are going to participate. But here is where the malice comes in: if they pay you, you 
are going to answer their questions. But if they keep asking you things, then you 
tell yourself: “Oh no, I am not going to tell them that.” You know? It would take 
some time for me to trust them; it wouldn’t be so fast.
(Participant K)
Participant H, who is homeless and lives in an abandoned house that also serves as shooting 
gallery, agrees: “I wouldn’t speak with them [researchers] the same way I speak with you. I 
would speak with them but I would make some things up … some would be total inventions, 
others not.”
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Others adopt a more principled approach: Not even the need to avoid the painful effects of 
withdrawal would be enough to induce them to participate in a study in which the 
researchers do not show “respect” for study participants. When asked, “Would you 
participate in a study with a significant financial compensation but where the researchers did 
not treat you with respect?” one participant responded:
No, not even being paid quite a bit of money. Why would you go to a place where 
you get paid but they don’t trust you, where they don’t give you respect? I am an 
addict but I am proud, you know? Something I don’t like is to be humiliated.
(Participant D)
Reciprocity
Although financial compensation is not enough to ensure trust, participants see it as the first 
step toward a trusting relationship based on reciprocity and respect. Researchers provide 
participants with financial support, and participants reciprocate by supporting the goals of 
the research enterprise. In the following quotes, participants describe how they understand 
compensation as an expression of respect and as part of a mutually beneficial exchange:
If you help me, you’re curing me, well, then, I give you the information you need 
and then we both helped each other.
(Participant L)
From the beginning you trusted me. I knew I could talk to you with the truth. Why 
[would I] lie if you are helping us? And then we help you, right?
(Participant D)
You have been very open. You asked us to help but you have nourished us. You 
have provided us with things that in other studies probably they wouldn’t care. I 
understand that some of the things you did were well beyond your responsibility. In 
turn, we are willing to be as sincere as possible and not hide anything because we 
want to support the study. You definitely should expect openness from us in return.
(Participant E)
Are gift cards as good as money?
Participants have a mixed view on receiving gift cards instead of cash incentives. For some, 
whether a gift card is acceptable depends on whether a participant is sick when he or she is 
approached to be part of the study. For these participants, a gift card would be a disincentive 
to enroll in a study: the holder would have trouble exchanging it for money and would be 
unlikely to get its equivalent in cash:
No, I wouldn’t do it because it is going to be very difficult to sell it. Of course, I 
wouldn’t use it myself. I would try to sell it on the street, but if I try to sell it 
nobody would give me its face value, I’d be lucky to sell it for $5 and that wouldn’t 
be enough to cure myself. So, no, if I am sick, I wouldn’t take it.
(Participant F)
Abadie et al. Page 8
Ethics Behav. Author manuscript; available in PMC 2019 October 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Yet, for others, a gift card, it is not a barrier to participation: “A gift card is money. 
Sure, with it I can buy something good”
(Participant M).
More entrepreneurial participants recognized that they could exchange the gift card 
for goods than could be sold later, in effect converting the gift card into cash: “Sure, 
a gift card is like money. I use it to buy something at Walmart, and whatever I buy 
there I sell and get the money back”
(Participant N).
DISCUSSION
Findings show that the prospect of receiving financial compensation is a strong motivation 
for participants to enroll in the study. Participants who inject very frequently, and thus 
require significant amounts of financial resources to afford their habit, are particularly 
motivated by the prospect of receiving cash for their participation. Yet financial gain is not 
the only motivation: Participants also value the possibility of receiving HIV/HCV tests in a 
trusting and confidential environment. The need to avoid the painful effects of heroin 
withdrawal might compel prospective participants to enroll, even when confidentiality or 
anonymity requirements are not in place, or despite other misgivings.
Yet the relationship between financial compensation and coercion, on one hand, and 
vulnerability, on the other, is not as clear as some literature suggests (Festinger et al., 2005). 
Some authors argue that IRBs tend to overemphasize participants’ vulnerability, seeing 
prospective research participants as prone to being abused by powerful researchers. In so 
doing, IRBs not only ignore participants’ autonomy but also might end up harming 
participants in their attempt to protect them from research risks (Juritzen, Grimen, & 
Heggen, 2011). In a related critique, Lamkin and colleagues (2018) argued that offering low 
payments for relatively high-risk situations exploits research participants.
As our study illustrates, marginalized research participants might be vulnerable but they are 
not without power. Pressured to participate in a research study because of the need to obtain 
cash, participants might resort to what Scott (1985) termed “weapons of the weak,” lying or 
omitting important information in an attempt to protect themselves and thus disrupting a 
study they do not trust. In addition, participants can further disrupt a study they see as 
illegitimate or coercive by harming the study’s reputation, by spreading negative views 
about it among their peers and potentially impacting the study even further (Devine et al., 
2013). As participants themselves acknowledge, the prospect of financial compensation and 
access to desirable services (Kamuya et al., 2014) might bring participants to the study’s 
door, but in and of itself, they cannot ensure a trusting relationship.
Participants in our study perceive trust as a process in which reciprocity pays a critical role. 
Financial compensation is perceived as an aspect of a relationship in which researchers 
support participants, not only financially but also by providing testing or other things that 
participants value. In turn, participants reciprocate by aligning with the goals of the study 
and providing a trustful account of their experiences. As Fisher (2011) and others have 
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argued, PWID exhibit complex moral reasoning; in this case, if they perceive that 
researchers are not fulfilling their obligations—proper financial compensation being one of 
them—then, participants, in turn, are relieved of theirs. Because money does not buy trust, 
perhaps we do not need to worry that excessive payments might represent an undue 
influence.
Furthermore, adequate financial compensation recognizes the expertise provided by research 
participants (Permuth-Wey & Borenstein, 2009) and provides a legitimate source of income, 
a welcome respite from illegal activities PWID may resort to in order to afford their habit, 
like sex work or drug dealing (DeBeck et al., 2007; Slomka, McCurdy, Ratliff, Timpson, & 
Williams, 2007). This suggests that, far from being potentially coercive, financial 
compensation can play a positive role for PWID who may come to feel valued members of a 
research enterprise.
Research on participants’ views of financial compensation suggests that participants 
appreciate more, not less, financial compensation (Barratt et al., 2007; Bell & Salmon, 2011; 
Oransky, Fisher, Mahadevan, & Singer, 2009). This finding has also been confirmed by 
Collins et al. (2017) in a similar study of HIV-positive PWID in Vancouver, Canada. Collins 
cautioned, however, that using gift cards or other modalities of compensation that do not 
involve cash can exacerbate existing power and social inequalities among research 
participants. Although some might be able to obtain the face value of a gift card, others with 
fewer resources or connections might receive less. Our findings, which show that 
participants with high-frequency drug use prefer to receive cash instead of a gift card, seem 
to corroborate this view while showing that providing a noncash form of compensation 
might not be, in itself, a barrier to participation.
The ethics of offering financial compensation to research participants has been extensively 
debated, including whether to impose some kind of limit on compensation to avoid creating 
an undue burden, or to experiment with noncash options (Davidson & Page, 2012; Ritter, 
Fry, & Swan, 2003). Yet these proposals should take into consideration that any measure that 
does not consider participants’ expectations for fair compensation risks jeopardizing the 
entire research enterprise (Oransky et al., 2009). Ultimately, it is the street “market,” not 
regulatory measures, that determines what type and level of financial compensation is 
considered adequate (Brown, Galea, Davidson, & Khoshnood, 2016). Dissatisfied 
prospective research participants might choose to “vote with their feet,” leaving researchers 
and the larger research enterprise vulnerable.
Strengths and limitations
This study has some limitations that arise from the composition of our sample. Because all 
of the participants had already been enrolled in a larger community health study among 
PWID in rural Puerto Rico, we did not gather the perspectives of those who had refused to 
participate in the parent study. However, because the focus of our study was not focused on 
barriers to participation but on how participants understand financial compensation, this 
limitation does not compromise the integrity of the study. Another limitation is that our 
sample included only men who were actively using intravenous drugs. Future studies aimed 
at assessing how women perceive financial payments in the context of community health 
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studies among PWID should be conducted. Because participants were paid to participate in 
this study about compensation, it is possible that this could have led to some kind of implicit 
response bias. A final limitation of this study was that there was no assessment of 
trustworthiness of the conclusions (given the relatively small data set, data were analyzed 
and interpreted by only one researcher). Despite these limitations, a major strength of this 
study is that the data are based not on hypothetical situations formulated to elicit 
participants’ views but on actual research experiences. We believe that this choice enhances 
the validity of this study.
Conclusion
This study shows that financial compensation was the main motivation for initially enrolling 
in the study for a large majority of participants, but access to HIV/HCV test results was also 
an important consideration. As trust in research developed with participants’ continuous 
involvement, participants came to perceive compensation as part of a reciprocal exchange in 
which they assisted researchers by providing a trustful account and researchers reciprocated 
with financial support. In this context, far from being perceived as an undue inducement, 
participants understood financial compensation as a fair exchange for the expertise they 
brought to the study. But if trust in the study is absent, financial compensation can lead 
participants to reassert themselves by deceiving researchers they feel are not fulfilling their 
obligations, thus compromising the validity of the study. These issues might be unique to the 
PWID, and those conducting research with this population should consider the role that 
financial compensation might play in prospective participants’ motivation to participate as 
well as the potential for a poorly structured financial compensation system to be construed 
by participants as coercive.
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TABLE 1
Results: Main Themes
Theme Definition Relevant Quote
Motivation Receiving financial compensation was initially the 
main motivation and in some cases, the only reason, 
to enroll in the study.
“I am hustling, always hustling and I could really use that money.” 
(Participant C)
Coercion The need to avoid the heroin withdrawal effects 
placed them in a relatively vulnerable position as 
prospective research participants.
“If one is sick [experiencing heroin withdrawal], desperate, it is true 
that the user can’t say “no”, you do whatever it has to be done.” 
(Participant I)
Trust Participants recognize that money, while initially 
ensuring their participation, can’t by itself buy trust
“Trust has nothing to do with [payment]” (Participant K)
Reciprocity Participants perceive financial compensation as an 
important step in the process of building trust.
“If you help me, you’re curing me, well, then I give you the 
information you need and then we both help each other.” 
(Participant L)
Cash 
payments
Participants have a mixed view on receiving gift cards 
instead of cash incentives.
“No, I wouldn’t do it because it is going to be
very difficult to sell it” (Participant F). “A gift card is money, sure, 
with it I can buy something good” (Participant M)
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